Leading medical minds from Harvard, Massachusetts General Hospital, the University of Miami and other major institutions will lend their expertise to Sienna Biopharmaceuticals Inc. as members of its newly established corporate advisory board.
The dermatology and medical aesthetics pharmaceutical firm, headquartered in Westlake Village, announced Tuesday that it had appointed 10 dermatologists specializing in psoriasis, eczema, itching conditions, acne and laser medicine to serve on the board. The group was established in preparation for Sienna’s 2018 initiatives, Chief Medical Officer Dr. Paul Lizzul said in a statement.
“This is exactly the right time for us to engage with these leading scientists and practitioners,” Lizzul said. “They have unique and varied viewpoints from years of research and clinical practice.”
The roster includes Dr. Jeffrey Dover, an associate professor of dermatology at Brown and Yale; Dr. Emma Guttman, director of the laboratory of inflammatory skin diseases at Mount Sinai’s Icahn School of Medicine; Lerner Medical Devices founder and Harvard associate professor Dr. Ethan Lerner; Dr. Diane Berson, an associate professor at Cornell’s Weill Cornell Medical College; Dr. Mathew Avram, director of laser, cosmetics and dermatologic surgery at Massachusetts General Hospital; Innovaderm Research Inc. founder Dr. Robert Bissonnette; Dr. Mitchel Goldman, medical director of Cosmetic Laser Dermatology in San Diego; Dr. Alan Menter, chairman of the dermatology division at Baylor University Medical Center; Dr. Sonja Ständer of University Hospital Münster in Germany; and Dr. Gil Yosipovitch, director of the University of Miami Miller School of Medicine’s Miami Itch Center.
Sienna stock (SNNA) rose $1.01, or 4.4 percent, on Tuesday to close at $23.75 on the Nasdaq.